Dohj LLC Sells 4,626 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Dohj LLC reduced its stake in IQVIA Holdings Inc. by 54.4% during Q2, selling 4,626 shares, and now holds 3,870 shares valued at approximately $569,000.
• IQVIA reported a quarterly earnings per share (EPS) of $2.81, exceeding estimates, and achieved a revenue of $4.02 billion, marking a 5.3% year-over-year growth.
• Institutional investors own 89.62% of IQVIA's stock, and the company has an average analyst rating of "Moderate Buy" with a target price around $230.32.

Dohj LLC decreased its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 54.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,870 shares of the medical research company's stock after selling 4,626 shares during the quarter. Dohj LLC's holdings in IQVIA were worth $569,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in IQV. Everpar Advisors LLC increased its position in IQVIA by 4.6% during the 2nd quarter. Everpar Advisors LLC now owns 1,404 shares of the medical research company's stock worth $221,000 after buying an additional 62 shares during the period. Ballentine Partners LLC raised its stake in IQVIA by 4.9% in the 1st quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company's stock worth $260,000 after purchasing an additional 69 shares in the last quarter. Independent Advisor Alliance boosted its holdings in IQVIA by 4.2% in the 1st quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company's stock valued at $318,000 after purchasing an additional 72 shares during the period. Nemes Rush Group LLC grew its position in shares of IQVIA by 15.0% during the 1st quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company's stock worth $109,000 after purchasing an additional 81 shares in the last quarter. Finally, Forte Capital LLC ADV raised its position in shares of IQVIA by 0.3% in the second quarter. Forte Capital LLC ADV now owns 26,809 shares of the medical research company's stock valued at $4,225,000 after buying an additional 92 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Price Performance

Shares of NYSE IQV opened at $200.66 on Wednesday. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $237.34. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. The firm has a fifty day simple moving average of $188.17 and a 200 day simple moving average of $167.81. The company has a market capitalization of $34.11 billion, a PE ratio of 29.04, a P/E/G ratio of 2.25 and a beta of 1.32.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.77 by $0.04. The company had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company's quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the firm posted $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently commented on IQV. Weiss Ratings reaffirmed a "hold (c)" rating on shares of IQVIA in a research note on Saturday, September 27th. Jefferies Financial Group raised IQVIA from a "hold" rating to a "buy" rating and raised their target price for the company from $195.00 to $225.00 in a report on Tuesday, September 9th. William Blair reissued an "outperform" rating on shares of IQVIA in a report on Wednesday, July 23rd. Barclays upped their price objective on IQVIA from $185.00 to $200.00 and gave the stock an "equal weight" rating in a research report on Thursday, October 2nd. Finally, Truist Financial boosted their target price on IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. Eighteen analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat.com, IQVIA currently has an average rating of "Moderate Buy" and an average price target of $230.32.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares in the company, valued at $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Keriann Cherofsky sold 549 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider owned 2,910 shares of the company's stock, valued at $557,352.30. The trade was a 15.87% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.